AI Insight
Two studies published in The Lancet and JAMA demonstrate that orforglipron effectively reduces HbA1c levels in patients with type 2 diabetes. The research examined orforglipron's efficacy in two patient groups: those using metformin and those taking insulin glargine. Both studies show beneficial effects on blood glucose control in these populations.
Why it matters
These findings suggest orforglipron could provide an additional treatment option for type 2 diabetes patients who need better glycemic control while on existing therapies. The drug's effectiveness in combination with commonly prescribed medications like metformin and insulin glargine could benefit millions of patients struggling to manage their blood sugar levels.
Orforglipron is beneficial for blood glucose control in individuals with type 2 diabetes using metformin or taking insulin glargine, according to two studies published online June 8 in The Lancet and the JAMA to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.
Source: ADA: Orforglipron beneficial for reducing HbA1c in type 2 diabetes